- Home
- IMAB vs ACRS Comparison
IMAB vs ACRS Comparison
Compare IMAB & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMAB
- ACRS
- Stock Information
- Founded
- IMAB 2014
- ACRS 2012
- Country
- IMAB United States
- ACRS United States
- Employees
- IMAB N/A
- ACRS N/A
- Industry
- IMAB Biotechnology: Pharmaceutical Preparations
- ACRS Biotechnology: Pharmaceutical Preparations
- Sector
- IMAB Health Care
- ACRS Health Care
- Exchange
- IMAB Nasdaq
- ACRS Nasdaq
- Market Cap
- IMAB 200.9M
- ACRS 165.7M
- IPO Year
- IMAB 2020
- ACRS 2015
- Fundamental
- Price
- IMAB $4.87
- ACRS $1.87
- Analyst Decision
- IMAB Strong Buy
- ACRS Strong Buy
- Analyst Count
- IMAB 3
- ACRS 9
- Target Price
- IMAB $6.33
- ACRS $9.25
- AVG Volume (30 Days)
- IMAB 4.2M
- ACRS 1.5M
- Earning Date
- IMAB 05-15-2025
- ACRS 08-07-2025
- Dividend Yield
- IMAB N/A
- ACRS N/A
- EPS Growth
- IMAB N/A
- ACRS N/A
- EPS
- IMAB N/A
- ACRS N/A
- Revenue
- IMAB N/A
- ACRS $16,789,000.00
- Revenue This Year
- IMAB N/A
- ACRS N/A
- Revenue Next Year
- IMAB N/A
- ACRS $8.11
- P/E Ratio
- IMAB N/A
- ACRS N/A
- Revenue Growth
- IMAB N/A
- ACRS N/A
- 52 Week Low
- IMAB $0.60
- ACRS $1.05
- 52 Week High
- IMAB $5.90
- ACRS $5.17
- Technical
- Relative Strength Index (RSI)
- IMAB 75.47
- ACRS 75.14
- Support Level
- IMAB $3.30
- ACRS $1.58
- Resistance Level
- IMAB $3.94
- ACRS $1.77
- Average True Range (ATR)
- IMAB 0.58
- ACRS 0.11
- MACD
- IMAB 0.23
- ACRS 0.02
- Stochastic Oscillator
- IMAB 76.12
- ACRS 94.25
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.